(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 6.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.07%.
Rigel Pharmaceuticals's revenue in 2026 is $299,767,000.On average, 7 Wall Street analysts forecast RIGL's revenue for 2026 to be $5,360,977,680, with the lowest RIGL revenue forecast at $5,086,036,771, and the highest RIGL revenue forecast at $5,581,522,474. On average, 7 Wall Street analysts forecast RIGL's revenue for 2027 to be $6,045,554,640, with the lowest RIGL revenue forecast at $5,563,390,435, and the highest RIGL revenue forecast at $6,883,143,802.
In 2028, RIGL is forecast to generate $6,710,704,416 in revenue, with the lowest revenue forecast at $5,985,422,880 and the highest revenue forecast at $8,452,860,269.